Treatment outcome and prognostic factors in PCNSL
Pimjai Niparuck,Paisarn Boonsakan,Taksayut Sutthippingkiat,Sulada Pukiat,Pichika Chantrathammachart,Sithakom Phusanti,Kochawan Boonyawat,Teeraya Puavilai,Pantep Angchaisuksiri,Artit Ungkanont,Suporn Chuncharunee,Vichai Atichartakarn
DOI: https://doi.org/10.1186/s13000-019-0833-1
2019-06-13
Diagnostic Pathology
Abstract:<h3 class="Heading">Objectives</h3><p class="Para">Standard treatment with a thiotepa-based regimen in countries with a limited resource is less feasible. Aims of the study were to evaluate the treatment outcome, and identify the prognostic factors in patients with primary central nervous system lymphoma (PCNSL).</p><h3 class="Heading">Methods</h3><p class="Para">We conducted a retrospective study of 43 patients diagnosed with PCNSL, DLBCL subtype, who were treated with either HDMTX-based regimen, whole brain radiotherapy (WBRT), or both between 2010 and 2017.</p><h3 class="Heading">Results</h3><p class="Para">There were 43 patients with a median age of 65 years (range 34–89 years). Protein expression of CD10, Bcl6, MUM1, Bcl2 and MYC were found in 19, 86, 91, 91 and 23%, respectively. Both germinal center B cell (GCB) and double-expressor (MYC+/Bcl2+) lymphomas were found in 21%. Multiple brain lesions and maximum tumor diameter (MTD) ≥5 cm were seen in 27 and 10 patients, respectively. Chemotherapy combined with WBRT, chemotherapy and WBRT were given to 20, 14 and 9 patients, respectively. Overall complete remission (CR) rate was 55.8%. Those receiving a combined-modality therapy had a higher CR rate than those treated with either chemotherapy (75% versus 36%, <em class="EmphasisTypeItalic">p =</em> 0.036) or WBRT (75% versus 44%, <em class="EmphasisTypeItalic">p =</em> 0.109). Median follow-up time was 17 months, and a 7-year overall survival (OS) was 40%. Features associated with a prolonged OS were an ECOG score ≤ 2 (<em class="EmphasisTypeItalic">p</em> = 0.001), multiple brain lesions (<em class="EmphasisTypeItalic">p</em> = 0.010), multiple area of brain involvement (<em class="EmphasisTypeItalic">p</em> = 0.023), MTD p = 0.004), GCB subtype (<em class="EmphasisTypeItalic">p</em> = 0.003) and positive CD10 staining (<em class="EmphasisTypeItalic">p</em> = 0.007). Expression of Bcl2 protein was associated with a significantly worse OS in the non-GCB DLBCL patients.</p><h3 class="Heading">Discussion</h3><p class="Para">The factors affecting treatment outcomes in PCNSL were cell of origin of DLBCL, lesion characteristics, patients' status and treatment regimen.</p>
pathology